8-K: PDS Biotech Seeks Accelerated FDA Approval for PDS0101

PDS Biotechnology reported Q3 2025 financial results and announced plans to seek an accelerated approval pathway for its lead immunotherapy, PDS0101, based on positive Phase 2 trial data.

Summary

• PDS Biotech completed the VERSATILE-002 Phase 2 clinical trial evaluating PDS0101 + Keytruda (pembrolizumab) in patients with HPV16+ recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
• The median overall survival (mOS) in patients with CPS ≥ 1 was 39.3 months, with the lower limit of the 95% confidence interval at 23.9 months and the upper limit not yet estimable.
• The progression-free survival (PFS) in patients with CPS ≥ 1 was 6.3 months.
• The company plans to seek an accelerated approval pathway for the VERSATILE-003 Phase 3 randomized trial, proposing to amend the statistical analysis plan to use PFS as a surrogate primary endpoint for accelerated approval, while mOS will remain the primary endpoint for full FDA approval.
• The National Cancer Institute (NCI) presented new clinical data at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, highlighting PDS01ADC and PDS0101.
• Preliminary results from the Colorectal Cancer Cohort of a Phase 2 clinical trial with PDS01ADC met criteria for expansion to Stage 2, achieving at least 6 of 9 confirmed objective responses by RECIST v1.1.
• Net loss for the three months ended September 30, 2025, was $9.0 million, or $0.19 per basic and diluted share, compared to $10.7 million, or $0.29 per basic and diluted share, for the same period in 2024.
• Research and development expenses decreased to $4.6 million in Q3 2025 from $6.8 million in Q3 2024.
• General and administrative expenses increased to $3.6 million in Q3 2025 from $3.4 million in Q3 2024.
• Total operating expenses decreased to $8.1 million in Q3 2025 from $10.2 million in Q3 2024.
• Net interest expense increased to $0.9 million in Q3 2025 from $0.5 million in Q3 2024, primarily due to lower interest income.
• Cash and cash equivalents as of September 30, 2025, were $26.2 million, down from $41.7 million as of December 31, 2024.
• On November 12, 2025, the company sold 5,800,000 common stock (or prefunded warrants) and 5,800,000 accompanying warrants for gross proceeds of approximately $5.3 million.

Sentiment

Score: 7

Explanation: The clinical trial results are very positive, particularly the mOS data, and the pursuit of an accelerated approval pathway is a strong strategic move. However, the company continues to burn cash and recently conducted a capital raise, indicating ongoing financial needs typical for a biotech at this stage.

Positives

• The VERSATILE-002 Phase 2 trial showed positive final topline survival data for PDS0101 + Keytruda in HPV16+ HNSCC, with a median overall survival (mOS) of 39.3 months in patients with CPS ≥ 1.
• The positive progression-free survival (PFS) data from VERSATILE-002 leads to a plan to seek an accelerated approval pathway for the VERSATILE-003 Phase 3 trial, potentially shortening trial duration and time to regulatory submission.
• The proposed amendment to the VERSATILE-003 trial could reduce trial size while maintaining statistical power.
• The PDS01ADC colorectal cancer cohort met criteria for expansion to Stage 2, achieving a high objective response rate of at least 6 of 9 confirmed objective responses.
• Net loss decreased to $9.0 million in Q3 2025 from $10.7 million in Q3 2024.
• Research and development expenses decreased by $2.2 million in Q3 2025 compared to Q3 2024.
• Total operating expenses decreased by $2.1 million in Q3 2025 compared to Q3 2024.

Negatives

• Cash and cash equivalents decreased to $26.2 million as of September 30, 2025, from $41.7 million as of December 31, 2024.
• Working capital decreased to $14.6 million as of September 30, 2025, from $28.0 million as of December 31, 2024.
• Long-term debt increased to $11.9 million as of September 30, 2025, from $9.2 million as of December 31, 2024.
• Accumulated deficit increased to $(209.0) million as of September 30, 2025, from $(182.1) million as of December 31, 2024.
• Total stockholders' equity decreased to $9.5 million as of September 30, 2025, from $19.0 million as of December 31, 2024.
• Net interest expense increased to $0.9 million in Q3 2025 from $0.5 million in Q3 2024, primarily due to lower interest income.

Risks

• Ability to protect intellectual property rights.
• Anticipated capital requirements, including cash runway and plans for future equity financings.
• Dependence on additional financing to fund operations and complete development and commercialization of product candidates, with risks that raising capital may restrict operations or require relinquishing rights to technologies or product candidates.
• Limited operating history in the current line of business, making it difficult to evaluate prospects, business plan, or successful implementation.
• Timing for conducting clinical trials for PDS0101 (Versamune HPV), PDS01ADC, PDS0103 (Versamune MUC1) and other Versamune based product candidates.
• Future success of clinical trials.
• Successful implementation of research and development programs and collaborations, including any collaboration studies, and the interpretation of their results and findings.
• Success, timing, and cost of ongoing and anticipated clinical trials, including statements regarding response rates, the timing of initiation, pace of enrollment and completion of the trials, futility analyses, presentations at conferences, data reported in an abstract, and receipt of interim or preliminary results.
• Ability to fully fund disclosed clinical trials, which assumes no material changes to currently projected expenses.
• Statements about understanding of product candidates' mechanisms of action and interpretation of preclinical and early clinical results from clinical development programs and collaboration studies.
• Ability to continue as a going concern.
• Other factors, including legislative, regulatory, political, and economic developments not within the company's control.

Future Outlook

PDS Biotech plans to meet with the FDA to propose an amendment to the VERSATILE-003 Phase 3 trial, aiming for an accelerated approval pathway by using progression-free survival (PFS) as a surrogate primary endpoint. This strategy is expected to shorten trial duration and time to regulatory submission, potentially accelerating treatment availability, while median overall survival (mOS) remains the primary endpoint for full FDA approval. The company also anticipates further development of its PDS01ADC program following positive Stage 1 results in colorectal cancer.

Management Comments

• "Our request to meet with the FDA to propose an amendment to our ongoing VERSATILE-003 Phase 3 trial represents the culmination of the encouraging data from our now completed VERSATILE-002 trial."
• "We believe the positive PFS data offers an important opportunity to shorten the trial duration and time to regulatory submission while maintaining mOS as the endpoint for full FDA approval."
• "Importantly, we believe this approach may also accelerate the availability of this promising treatment to patients in need."

Industry Context

The oncology immunotherapy space is highly competitive, with significant focus on combination therapies and accelerated approval pathways for promising treatments. PDS Biotech's strategy to combine PDS0101 with pembrolizumab (Keytruda, a widely used immune checkpoint inhibitor) aligns with industry trends seeking synergistic effects to improve patient outcomes in difficult-to-treat cancers like HPV16+ HNSCC. The pursuit of an accelerated approval pathway, leveraging positive Phase 2 PFS data, reflects a common industry approach to bring therapies to market faster for unmet medical needs, while still committing to full approval endpoints. The NCI's involvement and presentation of data at SITC underscore the scientific interest and potential validation of PDS Biotech's novel immunotherapy platforms.

Comparison to Industry Standards

• The median overall survival (mOS) of 39.3 months for PDS0101 + Pembrolizumab in HPV16+ HNSCC (CPS ≥ 1) is a strong result compared to historical data for pembrolizumab monotherapy in recurrent/metastatic HNSCC, which typically shows mOS in the range of 10-15 months (e.g., Keynote-048 trial showed mOS of 14.9 months for pembrolizumab monotherapy in PD-L1 CPS ≥ 20 patients).
• The progression-free survival (PFS) of 6.3 months for PDS0101 + Pembrolizumab in HPV16+ HNSCC (CPS ≥ 1) also appears favorable when compared to historical PFS rates for pembrolizumab monotherapy in similar patient populations, which are often in the range of 2-4 months.
• The company's strategy to seek accelerated approval based on PFS, while maintaining mOS for full approval, is a standard regulatory pathway utilized by many oncology companies to expedite patient access to therapies demonstrating significant clinical benefit.
• The expansion of the PDS01ADC colorectal cancer cohort to Stage 2 after meeting a high objective response rate bar (at least 6 of 9 confirmed responses) indicates promising early efficacy, aligning with the rigorous criteria often set for advancing novel oncology agents in clinical development.

Stakeholder Impact

• Shareholders: Potential for increased value due to positive clinical data and accelerated approval pathway, but also dilution from recent capital raise and ongoing cash burn.
• Patients: Accelerated availability of a promising treatment for HPV16+ HNSCC if FDA approval pathway is successful.
• Employees: Continued employment and potential growth opportunities as clinical programs advance.
• Regulatory Authorities (FDA): Engagement with the company regarding proposed trial amendments and potential accelerated approval.

Next Steps

• Meet with the FDA to propose an amendment to the VERSATILE-003 Phase 3 trial design.
• Potentially amend the statistical analysis plan for VERSATILE-003 to use PFS as a surrogate primary endpoint for accelerated approval.
• Continue the VERSATILE-003 trial with mOS as the primary endpoint for full FDA approval.
• Enrollment expansion for the PDS01ADC colorectal cancer study to Stage 2.
• Further clinical and translational findings from PDS Biotechnology's novel investigational immunotherapy platforms, including PDS01ADC and PDS0101.

Key Dates

Recommendation

The clinical data for PDS0101 in HPV16+ HNSCC is highly encouraging, particularly the median overall survival of 39.3 months, which significantly surpasses historical benchmarks. The strategic move to seek an accelerated approval pathway for the Phase 3 trial could expedite market access and is a strong positive. Additionally, the PDS01ADC program shows promise with its expansion to Stage 2 in colorectal cancer. However, the company's financial position shows a significant decrease in cash and working capital, and it recently completed a capital raise, indicating ongoing funding requirements. While the clinical progress is strong, the financial dilution and continued burn rate suggest a "hold" recommendation, advising investors to monitor the FDA's response to the accelerated approval request and the company's future financing activities before making further investment decisions. The long-term potential is high, but near-term financial risks warrant caution.

Keywords

PDS Biotech, PDSB, immunotherapy, cancer, HPV16, HNSCC, head and neck cancer, PDS0101, Keytruda, pembrolizumab, VERSATILE-002, VERSATILE-003, FDA accelerated approval, clinical trial, oncology, PDS01ADC, colorectal cancer, financial results, Q3 2025, net loss, R&D expenses, cash balance, warrants, capital raise